Esophageal cancer
Conditions
Interventions
DCF therapy
Sponsors
Kobe University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Endoscopic biopsy of the primary esophageal lesion has been histologically diagnosed as either squamous cell carcinoma or adenosquamous carcinoma 2 Clinical stage T1N1to3M0, T2to3N0to3M0 according to the UICC TNM 8th edition 3 18 years or older 4 Patient can receive initial DCF therapy without dose reduction 5 Performance status is 0 or 1 6 Patient has or not has measurable disease 7 Patients written consent to participate in the study has been obtained 8 Latest laboratory values within 14 days prior to enrollment meet all of the following White blood cell count more than 3000 Platelet count more than 10 Hemoglobin more than 10.0 Total bilirubin less than 1.5 AST less than 100 ALT less than 100 Serum creatinine less than 1.2 SpO2 more than 95 eGFR more than 60
Exclusion criteria
Exclusion criteria: 1. Patient has multiple cancers 2. Patient has active systemic infection 3. Patients who are not willing to use contraception and pregnant and lactating women 4. Psychosis or psychiatric comorbidities 5. History of hypersensitivity to docetaxelcisplatin or polysorbate 80 ontaining products 6. Patient has severe emphysema or pulmonary fibrosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of febrile neutropenia | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival Overall Survival Objective Response Rate pathological Complete Response R0 resection rate Adverse Event Suture failure rate Postoperative pneumonia rate | — |
Countries
Japan
Contacts
Public ContactYoshiaki Nagatani
Kobe University hospital Medical oncology and hematology
Outcome results
None listed